

# Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma

<b>Submission date</b> 02/11/2016	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 15/12/2016	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/03/2026	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-a-vaccine-for-cancers-who-tested-positive-to-the-human-papilloma-virus-hare-40>

## Contact information

### Type(s)

Public

### Contact name

Miss Izabela Eberhart

### Contact details

Southampton Clinical Trials Unit  
Southampton General Hospital  
MP131  
Tremona Road  
Southampton  
United Kingdom  
SO16 6YD  
+44 23 8120 3522  
HARE-40@soton.ac.uk

## Additional identifiers

### Clinical Trials Information System (CTIS)

2014-002061-30

### ClinicalTrials.gov (NCT)

NCT03418480

### Protocol serial number

30900

## Study information

### Scientific Title

Therapeutic HPV vaccine (BNT113) trial in HPV16 driven carcinoma

### Acronym

HARE-40

### Study objectives

The overall aim of this study is to establish a safe and tolerable dose of HPV mRNA vaccine and assess if there is evidence of clinical effect according to irRECIST 1.1.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approved 18/07/2016, London - West London & GTAC Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8098; westlondon.rec@hra.nhs.uk), ref: 16/LO/0567

### Study design

Non-randomized interventional study

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

HPV-driven squamous cell carcinoma

### Interventions

-

### Intervention Type

Biological/Vaccine

### Phase

Not Applicable

### Drug/device/biological/vaccine name(s)

BNT113

### Primary outcome(s)

Arm 1A:

The suitable dose of HPV mRNA vaccine is based on defined criteria for DLTs (dose limiting toxicities). This is measured by evaluation of DLTs until 28 days after last study treatment.

#### Arm 1B:

Disease control rate, defined as the rate of complete response, partial response or stable disease, is measured according to irRECIST 1.1 at the end of treatment CT scan at Day 85.

#### Key secondary outcome(s)

##### Arm 1A:

1. Adverse event rate is measured according to CTCAE v4.03 at the end of the trial until 28 days after last study treatment
2. Systemic levels of induced HPV-16 specific T-cell and B-cell immune responses are measured using specific biomarker tests at the end of study treatment
3. Duration of detectable vaccine-induced immune response is measured using specifically designed immune-assays at the end of study treatment
4. The clinical and immunological evaluation of DTH sites is assessed prior to vaccination and after the vaccination course, by clinical assessment and tissue biopsy, 48 hours post DTH injection

##### Arm 1B:

1. Adverse event rate is measured according to CTCAE v4.03 at the end of the trial until 28 days after last study treatment
2. Systemic levels of induced HPV-16 specific T-cell and B-cell immune responses are measured using specific biomarker tests during the course of trial at the end of study treatment
3. Duration of detectable vaccine-induced immune response is measured using specifically designed immune-assays, such as PBMCs during the course of the trial at the end of study treatment
4. The clinical and immunological evaluation of DTH sites is assessed prior to vaccination and after the vaccination course, by clinical assessment and tissue biopsy 48 hours post DTH injection
5. Percentage change in densities of immune cells in tumour tissue (where paired samples can be collected) is assessed using tumour tissue biopsies at baseline and follow-up (Day 85)
6. Numbers of immune cells is assessed by immunohistochemistry or flow cytometry at baseline and follow-up (Day 85)
7. Clinical response is measured according to irRECIST 1.1 at 85 days and 6 and 9 months
8. Disease control rate is measured according to irRECIST 1.1 at 6 and 9 months
9. Best overall response is measured according to irRECIST 1.1 at 9 months
10. Intra-tumoural levels of HPV16specific immune responses (where paired tumour samples can be collected) is measured using tumour tissue biopsies at baseline and follow-up (Day 85)
11. Safety/tolerability of HPV mRNA vaccine in terms of the adverse event rate is measured according to CTCAE v4.03 at 36 and 85 days
12. Grade 3 or above vaccine- or combination administration-related toxicity is measured within 90 days after the last administration of study drugs
13. Progression-Free Survival (PFS) is measured from baseline to date of disease progression or death, from any cause
14. Overall Survival (OS) is measured from baseline to date of disease progression or death, from any cause
15. Disease Specific Interval (DSI) is measured from baseline to date of disease progression or death, from any cause

#### Completion date

24/01/2024

## Eligibility

## **Key inclusion criteria**

### **Inclusion Criteria Arm 1A:**

1. Previous HPV16+ head and neck squamous cell carcinoma
2. At least 12 months after completion of treatment
3. Within 5 years of treatment completion
4. Currently no clinical evidence of disease
5. ECOG performance status 0 or 1
6. Able to provide written informed consent

### **Inclusion Criteria Arm 1B:**

1. HPV16+ head and neck, cervical, anogenital and penile carcinoma patients with recurrent disease.
2. Intention to treat is palliative.
3. Patient willing to have repeated tumour biopsies and re-biopsy deemed safe and feasible clinically.
4. Tissue samples available confirming HPV16+ disease to send to Central Laboratory.

## **Participant type(s)**

Patient

## **Healthy volunteers allowed**

No

## **Age group**

Mixed

## **Lower age limit**

18 years

## **Upper age limit**

110 years

## **Sex**

All

## **Total final enrolment**

15

## **Key exclusion criteria**

1. Patients unable to consent
2. Under 18 years of age
3. Systemic steroids or other drugs with a likely effect on immune competence are forbidden during the trial. The predictable need of their use will preclude the patient from trial entry. Replacement steroids for adrenal insufficiency/failure are allowed.
4. Major surgery in the preceding three to four weeks, which the patient has not yet recovered from
5. Patients who are of high medical risk because of non-malignant systemic disease, as well as those with active uncontrolled infection
6. Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease

7. Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study
8. Patients who are serologically positive for or are known to suffer from Hepatitis B, C, Syphilis or HIV. Counselling will be offered to all patients prior to testing
9. Patients who have a positive pregnancy test
10. Fertile males or females who are unable or unwilling to use a highly effective method of birth control (less than 1% per year, e.g. condom with spermicide, diaphragm with spermicide, birth control pills, injections, patches, intrauterine device, or intrauterine hormone-releasing system) during study treatment and until end of treatment +28 days (day 113)
11. Elevated Liver Function Tests – ALT, AST, Bilirubin
12. Any other investigational drug within 28 days or 5 half-lives depending on what gives the longer range before the first treatment of this study

**Date of first enrolment**

01/01/2017

**Date of final enrolment**

19/07/2023

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**University Hospital Southampton**  
Southampton University Hospital  
Tremona Road  
Southampton  
England  
SO16 6YD

**Study participating centre**

**The Christie NHS Foundation Trust**  
550 Wilmslow Road  
Withington  
Manchester  
England  
M20 4BX

## **Sponsor information**

## Organisation

University Hospital Southampton NHS Foundation Trust

## ROR

<https://ror.org/0485axj58>

## Funder(s)

### Funder type

Government

### Funder Name

European Commission

### Alternative Name(s)

European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Data sharing statement to be made available at a later date

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>			10/03/2026	No	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes